ClinicalTrials.gg
CompletedNCT01191489Updated Sep 12, 2014

High-flow Conditioned Oxygen Therapy Versus Non-invasive Ventilation: Prevention of Post-extubation Failure

A Phase 3 interventional study of High Flow Conditioned Oxygen Therapy in High Risk Patients and Non-invasive mechanical ventilation in Post-extubation Respiratory Failure, sponsored by Hospital Infanta Sofia. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-12.

Sponsored by Hospital Infanta Sofia · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
1,042
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main aim is to demonstrate whether the high flow conditioned oxygen therapy reduces the reintubation rate. Post-extubation respiratory failure risk will be stratified (as the randomization). In high risk patients high flow conditioned oxygen therapy will be compared with with not conditioned non-invasive mechanical ventilation. In low risk patients comparison will be conventional oxygen therapy. Hypercapnic patients will be excluded.

02

Conditions studied

  • Post-extubation Respiratory Failure
03

In context

Lead sponsor

Hospital Infanta Sofia is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Low Risk Patients:
  • Any extubated patients after tolerating a spontaneous breathing trial.
  • High Risk Patients:
  • Any extubated patients after >48 hours under mechanical ventilation and any of the following:
  • >65 years

    • cardiac failure as the primary indication of mechanical ventilation
    • APACHE II >12 points the extubation day
    • >30
    • inability to manage respiratory secretions

      • 1 failed spontaneous breathing trial
      • 1 comorbidity
      • 7 days under mechanical ventilation

Exclusion criteria

Exclusion Criteria:

  • \<18 years
  • thacheotomized patients
  • recent facial or cervical trauma/surgery
  • active gastro-intestinal bleeding
  • lack of cooperation and patients with any failed spontaneous breathing trial because of hypercapnia development.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,042 participants (actual)

Study arms

  • Experimental
    High Flow Conditioned Oxygen Therapy in high risk patients

    Device: High Flow Conditioned Oxygen Therapy in High Risk Patients

  • Active comparator
    Non-invasive mechanical ventilation in High Risk Patients

    Device: Non-invasive mechanical ventilation

  • Experimental
    High Flow Conditioned Oxygen Therapy in Low Risk Patients

    Device: High Flow Conditioned Oxygen Therapy in High Risk Patients

  • Active comparator
    Conventional Oxygen Therapy in Low Risk Patients

    Device: Conventional Oxygen Therapy

Interventions

  • DeviceHigh Flow Conditioned Oxygen Therapy in High Risk Patients

    OptiFlow system (R) with nasal cannula.

  • DeviceNon-invasive mechanical ventilation

    Bilevel pressure support through a facial mask

  • DeviceConventional Oxygen Therapy

    Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.

06

What researchers measure

Primary outcomes

  1. Post-extubation respiratory failure and Reintubation rate

    Time frame: 3 months

Secondary outcomes

  1. Intensive Care Unit mortality rate

    Time frame: 3 month

  2. Hospital mortality rate

    Time frame: 6 months

  3. Intensive Care Unit length of stay

    Time frame: 3 months

  4. Hospital length of stay

    Time frame: 6 months

  5. Nosocomial pneumonia rate

    Time frame: 3 months

  6. Tracheobronchitis rate

    Time frame: 3 months

07

Study locations

2 sites
  • Hospital Infanta Sofia
    San Sebastian de los Reyes, Madrid 28703, Spain
  • Hospital General de Ciudad Real
    Ciudad Real, 13005, Spain
08

References and documents

Publications

  • Hernandez G, Vaquero C, Colinas L, Cuena R, Gonzalez P, Canabal A, Sanchez S, Rodriguez ML, Villasclaras A, Fernandez R. Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial. JAMA. 2016 Oct 18;316(15):1565-1574. doi: 10.1001/jama.2016.14194. Erratum In: JAMA. 2016 Nov 15;316(19):2047-2048. doi: 10.1001/jama.2016.16337. JAMA. 2017 Feb 28;317(8):858. doi: 10.1001/jama.2017.0268. PubMed 27706464 ↗
  • Hernandez G, Vaquero C, Gonzalez P, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Colinas L, Cuena R, Fernandez R. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. JAMA. 2016 Apr 5;315(13):1354-61. doi: 10.1001/jama.2016.2711. PubMed 26975498 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01191489
Lead sponsor
Hospital Infanta Sofia
Responsible party
Gonzalo Hernandez Martinez (Gonzalo Hernandez Martinez, Hospital Infanta Sofia) — Principal investigator
First posted
Aug 30, 2010
Start date
Sep 2012
Primary completion
Sep 2014
Completion
Sep 2014
Last update
Sep 12, 2014

Study contacts

Gonzalo Hernandez, MD
study chair · Hospital Infanta Sofia

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion